Mason, Julie - University of Birmingham

个人简介

Julie Mason (née Simpson) graduated with a BSc (Hons) Pharmacy in 1994. After a pre-registration year in the community pharmacy sector, she became a registered pharmacist and continued to work in this field while undertaking a PhD in the ‘Synthesis and Biological Evaluation of Potential Anti-Cancer Agents’ at Aston University. Completing her PhD studies in 2000, Julie secured a position in the hospital pharmacy sector. Using her research and hospital pharmacy experience, Julie progressed to the position of Gene Therapy Pharmacist for the Early Drug Development team at the Institute for Cancer Studies, Clinical trials Unit, University of Birmingham. In this role for seven years, Julie maintained her technical pharmacy skills with an honorary contract for University Hospital Birmingham NHS Trust. In 2004, she completed her Diploma in Clinical Oncology at the University of Birmingham. An interest in the technical and manufacturing aspects of pharmacy led to various Quality Assurance Pharmacist roles for both NHS and private sector pharmaceutical specials manufacturing units for aseptically prepared products. During this time Julie became a committee member of the NHS Pharmaceutical Quality Assurance Research and Development group. Maintaining an interest in clinical research, Julie moved into a research support role in 2010 as Lead clinical trials pharmacist for Sandwell and West Birmingham Hospitals NHS Trust. Here, she developed training packages for pharmacy staff involved in clinical trials, while building and running a pharmacy clinical trials team and expanding the active trial portfolio for the Trust. In August 2014, Julie joined the staff at the College of Medicine and Dentistry as part of the team developing the MPharm undergraduate degree programme and new pharmaceutical initiatives at the University of Birmingham

研究领域

A particular area of interest is the delivery of NHS cancer services in relation to clinical trials.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Debruyne PR, Johnson PJ, Pottel L, Daniels S, Greer R, Hodgkinson E, Kelly S, Lycke M, Samol J, Mason J, Kimber D, Loucaides E, Parmar MKB and Harvey S on behalf of NIHR CRN-CPAS (2015) Optimisation of pharmacy content in clinical cancer research protocols: Experience of the United Kingdom Chemotherapy and Pharmacy Advisory Service. Clin Trials [Epub ahead of print] Lindsay C, Simpson J, Ispoglou S, Sturman SG and Pandyan AD (2014) The early use of botulinum toxin in post-stroke spasticity: study protocol for a randomised controlled trial. Trials 15(12) Santillo M, Barnes A, Douris G, Goddard G, Hiom S, Jackson M, Precious N, Simpson J and Weir P (2012) A standard protocol for deriving and assessment of stability. Part 2 – Aseptic Preparations (Biopharmaceuticals), Edition 1, NHS Pharmaceutical Quality Assurance Committee Santillo M, Goddard G, Hiom S, Jackson M, Precious N, Simpson J and Weir P (2010) A standard protocol for deriving and assessment of stability. Part 1 – Aseptic Preparations (Small Molecules), Version 2, NHS Pharmaceutical Quality Assurance Committee Hu JC, Coffin RS, Davies CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D and Coombes RC (2006) A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor. Clinical Cancer Research 12(22):6737-47 Simpson J (2006) Progress in Gene Therapy – are hospital pharmacies the next barrier? Hospital Pharmacist 13(8):266 Simpson J and Stoner NS (2003) Gene Therapy Implications for Hospital Pharmacy. Pharmaceutical Journal 271(7259):127-30 Simpson J, Forrester R, Tisdale MJ, Billington DC and Rathbone DL (2003) Effect of catechol derivatives on cell growth and lipoxygenase activity. Bioorg Med Chem Lett 13(15):2435-9